COBRRA: Apixaban vs Ribaroxaban en Tromboembolismo Venoso Agudo (NEJM 2026)

from Inercia Cero: Corazón, Riñón y Metabolismo · host Dr. Gilberto García Bernal

Instagram: ⁠@dr.gilbertogarciabernal⁠Infografías en X: ⁠@GilbertoG_MDBleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. COBRRA (N Engl J Med, 2026)Este estudio clínico aleatorizado evalúa la incidencia de hemorragias en pacientes con tromboembolismo venoso agudo tratados con apixabán o rivaroxabán.Los hallazgos principales revelan que apixabán presenta un perfil de seguridad superior, con un riesgo significativamente menor de sangrado mayor y no mayor clínicamente relevante.Ambos anticoagulantes mostraron una eficacia similar en la prevención de eventos trombóticos recurrentes durante el periodo de seguimiento de tres meses.

Episode metadata supplied by the publisher feed · Published Mar 15, 2026

Embed this episode

Attribution link and audio player

Ready to play

COBRRA: Apixaban vs Ribaroxaban en Tromboembolismo Venoso Agudo (NEJM 2026)

0:00 19:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Inercia Cero: Corazón, Riñón y Metabolismo?

This episode is 19 minutes long.

When was this Inercia Cero: Corazón, Riñón y Metabolismo episode published?

This episode was published on March 15, 2026.

Can I download this Inercia Cero: Corazón, Riñón y Metabolismo episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!